Malaria vaccine study for reducing Salmonella risk
Part of Infections clinical trials.
This study looks at whether malaria vaccines can also help lower the risk of a serious bacterial infection called invasive non-typhoidal Salmonella (iNTS). If you have a fever, you may be able to join and help researchers understand this connection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living in the area covered by the participating health center.
- You must have a fever that is at least 38.0°C (ear) or 37.5°C (armpit) when you come to the clinic.
- Or, you must have had a fever for 3 or more days in a row within the last week.
- You can be any age—children and adults are both welcome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the R21/Matrix-M malaria vaccine works in real-life settings for children under 5. If your child is eligible for the vaccine and has a fever, they may be able to join and help us understand the vaccine's impact.
This study tests a new malaria vaccine (called R21/MM) given in different doses and forms. If you qualify, you'll help find a better way to protect against malaria.
This trial tests a new malaria vaccine in healthy adults. It's an early (Phase 1) study, so it's mainly checking safety and how the body responds to the vaccine, not whether it prevents malaria yet.
This study screens healthy adults to see who can join future malaria vaccine or investigational malaria drug studies, including a controlled malaria exposure. It may help researchers test safer vaccines/drugs, but participation requires good health and strict medical eligibility.
This trial tests a new malaria vaccine in healthy children. It aims to see if the vaccine is safe and how well it works in children who have had their regular childhood shots.
This study looks at lab tests for malaria vaccine candidates in pregnant women who currently have malaria. It may help researchers understand which vaccine approaches are safest and most promising for pregnancy.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.